Genetics and vascular biology of brain vascular malformations

Stroke: Pathophysiology, Diagnosis, and Management

Volumn , Issue , 2011, Pages 169-186

  Kim, Helen ^a   Pawlikowska, Ludmila ^b   Young, William L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85136923970     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5478-8.10012-0     Document Type: Chapter

References (240)

1. Arteriovenous malformations of the brain in adults. N Engl J Med 1999, 340:1812-1818. Arteriovenous Malformation Study Group.
2. Al-Shahi R., Fang J.S., Lewis S.C., et al. Prevalence of adults with brain arteriovenous malformations: A community based study in Scotland using capture-recapture analysis. J Neurol Neurosurg Psychiatry 2002, 73:547-551.
3. Berman M.F., Sciacca R.R., Pile-Spellman J., et al. The epidemiology of brain arteriovenous malformations. Neurosurgery 2000, 47:389-396.
4. Stapf C., Mast H., Sciacca R.R., et al. The New York Islands AVM Study: Design, study progress, and initial results. Stroke 2003, 34:e29-e33.
5. Gabriel R.A., Kim H., Sidney S., et al. Ten-year detection rate of brain arteriovenous malformations in a large, multiethnic, defined population. Stroke 2010, 41:21-26.
6. Kim H., Sidney S., McCulloch C.E., et al. Racial/ethnic differences in longitudinal risk of intracranial hemorrhage in brain arteriovenous malformation patients. Stroke 2007, 38:2430-2437.
7. Potter C.A., Armstrong-Wells J., Fullerton H.J., et al. Neonatal giant pial arteriovenous malformation: Genesis or rapid enlargement in the third trimester. J Neurointervent Surg 2009, 1:151-153.
8. Kim H., McCulloch C.E., Johnston S.C., et al. Comparison of two approaches for determining the natural history risk of brain arteriovenous malformation (BAVM) rupture. Am J Epidemiol 2010, 171:1317-1322.
9. Du R., Hashimoto T., Tihan T., et al. Growth and regression of an arteriovenous malformation in a patient with hereditary hemorrhagic telangiectasia: Case report. J Neurosurg 2007, 106:470-477.
10. Hino A., Fujimoto M., Iwamoto Y., et al. An adult case of recurrent arteriovenous malformation after "complete" surgical excision: A case report. Surg Neurol 1999, 52:156-158.
11. Kader A., Goodrich J.T., Sonstein W.J., et al. Recurrent cerebral arteriovenous malformations after negative postoperative angiograms. J Neurosurg 1996, 85:14-18.
12. Klimo P., Rao G., Brockmeyer D. Pediatric arteriovenous malformations: A 15-year experience with an emphasis on residual and recurrent lesions. Childs Nerv Syst 2007, 23:31-37.
13. Lindqvist M., Karlsson B., Guo W.Y., et al. Angiographic long-term follow-up data for arteriovenous malformations previously proven to be obliterated after gamma knife radiosurgery. Neurosurgery 2000, 46:803-808.
14. Hashimoto T., Mesa-Tejada R., Quick C.M., et al. Evidence of increased endothelial cell turnover in brain arteriovenous malformations. Neurosurgery 2001, 49:124-131.
15. Hashimoto T., Lawton M.T., Wen G., et al. Gene microarray analysis of human brain arteriovenous malformations. Neurosurgery 2004, 54:410-423.
16. Lee C.Z., Xue Z., Zhu Y., et al. Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracranial hemorrhage. Stroke 2007, 38:2563-2568.
17. Chen Y., Xu B., Arderiu G., et al. Retroviral delivery of homeobox d3 gene induces cerebral angiogenesis in mice. J Cereb Blood Flow Metab 2004, 24:1280-1287.
18. Zhu Y., Cuevas I.C., Gabriel R.A., et al. Restoring transcription factor HoxA5 expression inhibits the growth of experimental hemangiomas in the brain. J Neuropathol Exp Neurol 2009, 68:626-632.
19. Hashimoto T., Lam T., Boudreau N.J., et al. Abnormal balance in the angiopoietin-Tie2 system in human brain arteriovenous malformations. Circ Res 2001, 89:111-113.
20. Hashimoto T., Wen G., Lawton M.T., et al. Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations. Stroke 2003, 34:925-931.
21. Chen Y., Fan Y., Poon K.Y., et al. MMP-9 expression is associated with leukocytic but not endothelial markers in brain arteriovenous malformations. Front Biosci 2006, 11:3121-3128.
22. Chen Y., Pawlikowska L., Yao J.S., et al. Interleukin-6 involvement in brain arteriovenous malformations. Ann Neurol 2006, 59:72-80.
23. Chen Y., Zhu W., Bollen A.W., et al. Evidence for inflammatory cell involvement in brain arteriovenous malformations. Neurosurgery 2008, 62:1340-1349.
24. Shenkar R., Shi C., Check I.J., et al. Concepts and hypotheses: Inflammatory hypothesis in the pathogenesis of cerebral cavernous malformations. Neurosurgery 2007, 61:693-702.
25. Hao Q., Liu J., Pappu R., et al. Contribution of bone marrow-derived cells associated with brain angiogenesis is primarily through leucocytes and macrophages. Arterioscler Thromb Vasc Biol 2008, 28:2151-2157.
26. Hao Q., Chen Y., Zhu Y., et al. Neutrophil depletion decreases VEGF-induced focal angiogenesis in the mature mouse brain. J Cereb Blood Flow Metab 2007, 27:1853-1860.
27. Ota R., Kurihara C., Tsou T.L., et al. Roles of matrix metalloproteinases in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab 2009, 29:1547-1558.
28. Nuki Y., Matsumoto M.M., Tsang E., et al. Roles of macrophages in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab 2009, 29:495-503.
29. ten Dijke P., Arthur H.M. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007, 8:857-869.
30. ten Dijke P., Goumans M.J., Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008, 11:79-89.
31. Lebrin F., Mummery C.L. Endoglin-mediated vascular remodeling: Mechanisms underlying hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 2008, 18:25-32.
32. Revencu N., Boon L., Vikkula M. Arteriovenous malformation in mice and men (Chapter 21). Tumor Angiogenesis, Part 2 2008, 363-374. Springer, Berlin. D. Marmé, N. Fusenig (Eds.).
33. Bernabeu C., Conley B.A., Vary C.P. Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem 2007, 102:1375-1388.
34. Marchuk D.A., Srinivasan S., Squire T.L., et al. Vascular morphogenesis: Tales of two syndromes. Hum Mol Genet 2003, 12:R97-R112.
35. Abdalla S.A., Letarte M. Hereditary haemorrhagic telangiectasia: Current views on genetics and mechanisms of disease. J Med Genet 2006, 43:97-110.
36. Lux A., Attisano L., Marchuk D.A. Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1. J Biol Chem 1999, 274:9984-9992.
37. Scharpfenecker M., van Dinther M., Liu Z., et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007, 120:964-972.
38. Barbara N.P., Wrana J.L., Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999, 274:584-594.
39. David L., Mallet C., Mazerbourg S., et al. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) endothelial cells. Blood 2007, 109:1953-1961.
40. Urness L.D., Sorensen L.K., Li D.Y. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000, 26:328-331.
41. Park S.O., Lee Y.J., Seki T., et al. ALK5-and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2 (HHT2). Blood 2008, 111:633-642.
42. Gallione C.J., Richards J.A., Letteboer T.G., et al. SMAD4 mutations found in unselected HHT patients. J Med Genet 2006, 43:793-797.
43. Bayrak-Toydemir P., McDonald J., Akarsu N., et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 2006, 140:2155-2162.
44. Cole S.G., Begbie M.E., Wallace G.M., et al. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005, 42:577-582.
45. Lamouille S., Mallet C., Feige J.J., et al. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 2002, 100:4495-4501.
46. David L., Mallet C., Vailhe B., et al. Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: Potential roles for JNK and ERK. J Cell Physiol 2007, 213:484-489.
47. Goumans M.J., Valdimarsdottir G., Itoh S., et al. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002, 21:1743-1753.
48. Seki T., Yun J., Oh S.P. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res 2003, 93:682-689.
49. Jonker L., Arthur H.M. Endoglin expression in early development is associated with vasculogenesis and angiogenesis. Mech Dev 2002, 110:193-196.
50. Abdalla S.A., Pece-Barbara N., Vera S., et al. Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. Hum Mol Genet 2000, 9(8):1227-1237.
51. Cymerman U., Vera S., Pece-Barbara N., et al. Identification of hereditary hemorrhagic telangiectasia type 1 in newborns by protein expression and mutation analysis of endoglin. Pediatr Res 2000, 47:24-35.
52. Sanz-Rodriguez F., Fernandez L.A., Zarrabeitia R., et al. Mutation analysis in Spanish patients with hereditary hemorrhagic telangiectasia: Deficient endoglin up-regulation in activated monocytes. Clin Chem 2004, 50:2003-2011.
53. van Laake L.W., van den Driesche S., Post S., et al. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation 2006, 114:2288-2297.
54. Matsubara S., Bourdeau A., terBrugge K.G., et al. Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations. Stroke 2000, 31:2653-2660.
55. Chen G.Z., Li T.L., Quan W., et al. [Expression of TGFbeta1 and its type I receptors ALK1 and ALK5 mRNA in brain arteriovenous malformation]. Nan Fang Yi Ke Da Xue Xue Bao 2006, 26:675-677.
56. Carvalho R.L., Itoh F., Goumans M.J., et al. Compensatory signalling induced in the yolk sac vasculature by deletion of TGFbeta receptors in mice. J Cell Sci 2007, 120:4269-4277.
57. Yang L.T., Li W.Y., Kaartinen V. Tissue-specific expression of Cre recombinase from the Tgfb3 locus. Genesis 2008, 46:112-118.
58. Toporsian M., Gros R., Kabir M.G., et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005, 96:684-692.
59. Toporsian M., Jerkic M., Zhou Y.Q., et al. Spontaneous adult-onset pulmonary arterial hypertension attributable to increased endothelial oxidative stress in a murine model of hereditary hemorrhagic telangiectasia. Arterioscler Thromb Vasc Biol 2010, 30:509-517.
60. Quick C.M., Hashimoto T., Young W.L. Lack of flow regulation may explain the development of arteriovenous malformations. Neurol Res 2001, 23:641-644.
61. Jerkic M., Rivas-Elena J.V., Prieto M., et al. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 2004, 18:609-611.
62. Belik J., Jerkic M., McIntyre B.A., et al. Age-dependent endothelial nitric oxide synthase uncoupling in pulmonary arteries of endoglin heterozygous mice. Am J Physiol Lung Cell Mol Physiol 2009, 297:L1170-1178.
63. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:642-649.
64. Chen Y., Hao Q., Kim H., et al. Soluble endoglin modulates aberrant cerebral vascular remodeling. Ann Neurol 2009, 66:19-27.
65. Velasco S., Alvarez-Munoz P., Pericacho M., et al. L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci 2008, 121:913-919.
66. Velasco-Loyden G., Arribas J., Lopez-Casillas F. The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J Biol Chem 2004, 279:7721-7733.
67. Hashimoto T., Matsumoto M., Li J.F., et al. Suppression of MMP-9 by doxycycline in brain arteriovenous malformations. BMC Neurol 2005, 5:1.
68. Pawlikowska L., Tran M.N., Achrol A.S., et al. Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. Stroke 2004, 35:2294-2300.
69. Achrol A.S., Pawlikowska L., McCulloch C.E., et al. Tumor necrosis factor-alpha-238G>A promoter polymorphism is associated with increased risk of new hemorrhage in the natural course of patients with brain arteriovenous malformations. Stroke 2006, 37:231-234.
70. Kim H., Hysi P.G., Pawlikowska L., et al. Common variants in interleukin-1-beta gene are associated with intracranial hemorrhage and susceptibility to brain arteriovenous malformation. Cerebrovasc Dis 2009, 27:176-182.
71. Cudmore M., Ahmad S., Al-Ani B., et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007, 115:1789-1797.
72. Matsubara S., Mandzia J.L., ter Brugge K., et al. Angiographic and clinical characteristics of patients with cerebral arteriovenous malformations associated with hereditary hemorrhagic telangiectasia. AJNR Am J Neuroradiol 2000, 21:1016-1020.
73. Maher C.O., Piepgras D.G., Brown R.D., et al. Cerebrovascular manifestations in 321 cases of hereditary hemorrhagic telangiectasia. Stroke 2001, 32:877-882.
74. Letteboer T.G., Mager J.J., Snijder R.J., et al. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 2006, 43:371-377.
75. Bayrak-Toydemir P., McDonald J., Markewitz B., et al. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: Mutations and manifestations. Am J Med Genet A 2006, 140:463-470.
76. Sabba C., Pasculli G., Lenato G.M., et al. Hereditary hemorrhagic telangiectasia: Clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007, 5:1149-1157.
77. Mast H., Young W.L., Koennecke H.C., et al. Risk of spontaneous haemorrhage after diagnosis of cerebral arteriovenous malformation. Lancet 1997, 350:1065-1068.
78. Inoue S., Liu W., Inoue K., et al. Combination of linkage and association studies for brain arteriovenous malformation. Stroke 2007, 38:1368-1370.
79. van Beijnum J., van der Worp H.B., Schippers H.M., et al. Familial occurrence of brain arteriovenous malformations: A systematic review. J Neurol Neurosurg Psychiatry 2007, 78:1213-1217.
80. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet 1990, 46:222-228.
81. Meschia J.F., Brown R.D., Brott T.G., et al. The Siblings With Ischemic Stroke Study (SWISS) protocol. BMC Med Genet 2002, 3:1.
82. Carter N., Williamson L., Kennedy L.G., et al. Susceptibility to ankylosing spondylitis. Rheumatology, (Oxford) 2000, 39:445.
83. Ritvo E.R., Jorde L.B., Mason-Brothers A., et al. The UCLA-University of Utah epidemiologic survey of autism: Recurrence risk estimates and genetic counseling. Am J Psychiatry 1989, 146:1032-1036.
84. Kim H., Marchuk D.A., Pawlikowska L., et al. Genetic considerations relevant to intracranial hemorrhage and brain arteriovenous malformations. Acta Neurochir (Suppl) 2008, 105:199-206.
85. Rogers M.S., D'Amato R.J. The effect of genetic diversity on angiogenesis. Exp Cell Res 2006, 312:561-574.
86. Shaked Y., Bertolini F., Man S., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005, 7:101-111.
87. Pawlikowska L., Tran M.N., Achrol A.S., et al. Polymorphisms in transforming growth factor-?-related genes ALK1 and ENG are associated with sporadic brain arteriovenous malformations. Stroke 2005, 36:2278-2280.
88. Simon M., Franke D., Ludwig M., et al. Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system. J Neurosurg 2006, 104:945-949.
89. Simon M., Schramm J., Ludwig M., et al. Author reply to letter by Young WL, et al, "Arteriovenous malformation". J Neurosurg 2007, 106:732-733.
90. Cambier S., Gline S., Mu D., et al. Integrin alpha(v)beta8-mediated activation of transforming growth factor-beta by perivascular astrocytes: An angiogenic control switch. Am J Pathol 2005, 166:1883-1894.
91. Su H., Kim H., Pawlikowska L., et al. Reduced expression of integrin alphavbeta8 is associated with brain arteriovenous malformation pathogenesis. Am J Pathol 2010, 176:1018-1027.
92. Kim H., Hysi P.G., Pawlikowska L., et al. Population stratification in a case-control study of brain arteriovenous malformation in Latinos. Neuroepidemiology 2008, 31:224-228.
93. Pawlikowska L., Poon K.Y., Achrol A.S., et al. Apoliprotein E epsilon2 is associated with new hemorrhage risk in brain arteriovenous malformation. Neurosurgery 2006, 58:838-843.
94. Achrol A.S., Kim H., Pawlikowska L., et al. Association of tumor necrosis factor-alpha-238G>A and apolipoprotein E2 polymorphisms with intracranial hemorrhage after brain arteriovenous malformation treatment. Neurosurgery 2007, 61:731-739.
95. Weinsheimer S., Kim H., Pawlikowska L., et al. EPHB4 gene polymorphisms and risk of intracranial hemorrhage in patients with brain arteriovenous malformations. Circ Cardiovasc Genet 2009, 2:476-482.
96. Woo D., Sauerbeck L.R., Kissela B.M., et al. Genetic and environmental risk factors for intracerebral hemorrhage: Preliminary results of a population-based study. Stroke 2002, 33:1190-1195.
97. O'Donnell H.C., Rosand J., Knudsen K.A., et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000, 342:240-245.
98. Langer D.J., Lasner T.M., Hurst R.W., et al. Hypertension, small size, and deep venous drainage are associated with risk of hemorrhagic presentation of cerebral arteriovenous malformations. Neurosurgery 1998, 42:481-486.
99. Frazer K.A., Ballinger D.G., Cox D.R., et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449:851-861.
100. Schunkert H., Gotz A., Braund P., et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation 2008, 117:1675-1684.
101. Kim H., Pawlikowska L., Weinsheimer S., et al. Genome-wide association study of intracranial hemorrhage in brain arteriovenous malformation (BAVM) patients [abstract]. Stroke 2010, 41:e11. (P37).
102. Vikkula M., Boon L.M., Carraway K.L., et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996, 87:1181-1190.
103. Calvert J.T., Riney T.J., Kontos C.D., et al. Allelic and locus heterogeneity in inherited venous malformations. Hum Mol Genet 1999, 8:1279-1289.
104. Brouillard P., Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet 2007, 16(Spec No. 2):R140-R149.
105. Limaye N., Wouters V., Uebelhoer M., et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 2009, 41:118-124.
106. Akers A.L., Johnson E., Steinberg G.K., et al. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCM): Evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet 2009, 18:919-930.
107. Happle R. Paradominant inheritance: A possible explanation for Becker's pigmented hairy nevus. Eur J Dermatol 1992, 2:39-40.
108. Happle R. Klippel-Trenaunay syndrome: Is it a paradominant trait?. Br J Dermatol 1993, 128:465-466.
109. Spetzler R.F., Wilson C.B., Weinstein P., et al. Normal perfusion pressure breakthrough theory. Clin Neurosurg 1978, 25:651-672.
110. Scott B.B., McGillicuddy J.E., Seeger J.F., et al. Vascular dynamics of an experimental cerebral arteriovenous shunt in the primate. Surg Neurol 1978, 10:34-38.
111. Bederson J.B., Wiestler O.D., Brustle O., et al. Intracranial venous hypertension and the effects of venous outflow obstruction in a rat model of arteriovenous fistula. Neurosurgery 1991, 29:341-350.
112. Chaloupka J.C., Vinuela F., Robert J., et al. An in vivo arteriovenous malformation model in swine: Preliminary feasibility and natural history study. AJNR Am J Neuroradiol 1994, 15:945-950.
113. De Salles A.A.F., Solberg T.D., Mischel P., et al. Arteriovenous malformation animal model for radiosurgery: The rete mirabile. AJNR Am J Neuroradiol 1996, 17:1451-1458.
114. Herman J.M., Spetzler R.F., Bederson J.B., et al. Genesis of a dural arteriovenous malformation in a rat model. J Neurosurg 1995, 83:539-545.
115. Lawton M.T., Jacobowitz R., Spetzler R.F. Redefined role of angiogenesis in the pathogenesis of dural arteriovenous malformations. J Neurosurg 1997, 87:267-274.
116. Morgan M.K., Anderson R.E., Sundt T.M. A model of the pathophysiology of cerebral arteriovenous malformations by a carotid-jugular fistula in the rat. Brain Res 1989, 496:241-250.
117. Kutluk K., Schumacher M., Mironov A. The role of sinus thrombosis in occipital dural arteriovenous malformations-development and spontaneous closure. Neurochirurgia (Stuttg) 1991, 34:144-147.
118. Terada T., Higashida R.T., Halbach V.V., et al. Development of acquired arteriovenous fistulas in rats due to venous hypertension. J Neurosurg 1994, 80:884-889.
119. TerBrugge K.G., Lasjaunias P., Hallacq P. Experimental models in interventional neuroradiology. AJNR Am J Neuroradiol 1991, 12:1029-1033.
120. Kailasnath P., Chaloupka J.C. Mathematical modeling of AVM physiology using compartmental network analysis: Theoretical considerations and preliminary in vivo validation using a previously developed animal model. Neurol Res 1996, 18:361-366.
121. Massoud T.F., Ji C., Vinuela F., et al. Laboratory simulations and training in endovascular embolotherapy with a swine arteriovenous malformation model. AJNR Am J Neuroradiol 1996, 17:271-279.
122. Massoud T.F., Ji C., Vinuela F., et al. An experimental arteriovenous malformation model in swine: Anatomic basis and construction technique. AJNR Am J Neuroradiol 1994, 15:1537-1545.
123. Morgan M.K., Anderson R.E., Sundt T.M. The effects of hyperventilation on cerebral blood flow in the rat with an open and closed carotid-jugular fistula. Neurosurgery 1989, 25:606-611.
124. Murayama Y., Massoud T.F., Vinuela F. Hemodynamic changes in arterial feeders and draining veins during embolotherapy of arteriovenous malformations: An experimental study in a swine model. Neurosurgery 1998, 43:96-104.
125. Nagasawa S., Kawanishi M., Kondoh S., et al. Hemodynamic simulation study of cerebral arteriovenous malformations. Part 2. Effects of impaired autoregulation and induced hypotension. J Cereb Blood Flow Metab 1996, 16:162-169.
126. Pietila T.A., Zabramski J.M., Thellier-Janko A., et al. Animal model for cerebral arteriovenous malformation. Acta Neurochir (Wien) 2000, 142:1231-1240.
127. Tu J., Karunanayaka A., Windsor A., et al. Comparison of an animal model of arteriovenous malformation with human arteriovenous malformation. J Clin Neurosci 2010, 17:96-102.
128. Young W.L., Kader A., Ornstein E., et al. Cerebral hyperemia after arteriovenous malformation resection is related to "breakthrough" complications but not to feeding artery pressure. Columbia University AVM Study Project. Neurosurgery 1996, 38:1085-1093.
129. Massoud T.F., Vinters H.V., Chao K.H., et al. Histopathologic characteristics of a chronic arteriovenous malformation in a swine model: preliminary study. AJNR Am J Neuroradiol 2000, 21:1268-1276.
130. Torsney E., Charlton R., Diamond A.G., et al. Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation 2003, 107:1653-1657.
131. Srinivasan S., Hanes M.A., Dickens T., et al. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 2003, 12:473-482.
132. Satomi J., Mount R.J., Toporsian M., et al. Cerebral vascular abnormalities in a murine model of hereditary hemorrhagic telangiectasia. Stroke 2003, 34:783-789.
133. Park S.O., Wankhede M., Lee Y.J., et al. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 2009, 119:3487-3496.
134. Walker E., Shen F., Halprin R., et al. Regional deletion of Smad4 plus VEGF stimulation leads to vascular dysplasia in the adult mouse brain [abstract]. Stroke 2010, 41:e20. (#68).
135. Xu B., Wu Y.Q., Huey M., et al. Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain. J Cereb Blood Flow Metab 2004, 24:237-244.
136. Hao Q., Su H., Marchuk D.A., et al. Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation. Am J Physiol Heart Circ Physiol 2008, 295:H2250-H2256.
137. McCormick W.F. Pathology of vascular malformations of the brain. Intracranial Arteriovenous Malformations 1984, 44-63. Williams & Wilkins, Baltimore. C.B. Wilson, B.M. Stein (Eds.).
138. Attia W., Tada T., Hongo K., et al. Microvascular pathological features of immediate perinidal parenchyma in cerebral arteriovenous malformations: giant bed capillaries. J Neurosurg 2003, 98:823-827.
139. Sato S., Kodama N., Sasaki T., et al. Perinidal dilated capillary networks in cerebral arteriovenous malformations. Neurosurgery 2004, 54:163-168.
140. Zhang G., Zhou J., Fan Q., et al. Arterial-venous endothelial cell fate is related to vascular endothelial growth factor and Notch status during human bone mesenchymal stem cell differentiation. FEBS Lett 2008, 582:2957-2964.
141. Benedito R., Roca C., Sorensen I., et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009, 137:1124-1135.
142. ZhuGe Q., Zhong M., Zheng W., et al. Notch1 signaling is activated in brain arteriovenous malformation in humans. Brain 2009, 132:3231-3241.
143. Murphy P.A., Lu G., Shiah S., et al. Endothelial Notch signaling is upregulated in human brain arteriovenous malformations and a mouse model of the disease. Lab Invest 2009, 89:971-982.
144. Murphy P.A., Lam M.T., Wu X., et al. Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice. Proc Natl Acad Sci U S A 2008, 105:10901-10906.
145. Lee C.Z., Xu B., Hashimoto T., et al. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 2004, 35:1715-1719.
146. Lee C.Z., Yao J.S., Huang Y., et al. Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab 2006, 26:1157-1164.
147. Niimi H., Pardali K., Vanlandewijck M., et al. Notch signaling is necessary for epithelial growth arrest by TGF-beta. J Cell Biol 2007, 176:695-707.
148. Wang X., Mao X., Xie L., et al. Involvement of Notch1 signaling in neurogenesis in the subventricular zone of normal and ischemic rat brain in vivo. J Cereb Blood Flow Metab 2009, 29:1644-1654.
149. Chaudhary M.Y., Sachdev V.P., Cho S.H., et al. Dural arteriovenous malformation of the major venous sinuses: An acquired lesion. AJNR Am J Neuroradiol 1982, 3:13-19.
150. Nabors M.W., Azzam C.J., Albanna F.J., et al. Delayed postoperative dural arteriovenous malformations. Report of two cases. J Neurosurg 1987, 66:768-772.
151. Brown R.D., Flemming K.D., Meyer F.B., et al. Natural history, evaluation, and management of intracranial vascular malformations. Mayo Clin Proc 2005, 80:269-281.
152. Hashimoto T., Wu Y., Lawton M.T., et al. Co-expression of angiogenic factors in brain arteriovenous malformations. Neurosurgery 2005, 56:1058-1065.
153. Zhu Y., Lawton M.T., Du R., et al. Expression of hypoxia-inducible factor-1 and vascular endothelial growth factor in response to venous hypertension. Neurosurgery 2006, 59:687-696.
154. Gao P., Zhu Y., Ling F., et al. Nonischemic cerebral venous hypertension promotes a pro-angiogenic state through HIF-1 downstream genes and leukocyte-derived MMP-9. J Cereb Blood Flow Metab 2009, 29:1482-1490.
155. Young W.L. Intracranial arteriovenous malformations: Pathophysiology and hemodynamics (Chapter 6). Vascular Malformations of the Central Nervous System 1999, 95-126. Lippincott Williams & Wilkins, New York. J.J. Jafar, I.A. Awad, R.H. Rosenwasser (Eds.).
156. Frenzel T., Lee C.Z., Kim H., et al. Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: Pilot study of adverse events and tolerance. Cerebrovasc Dis 2008, 25:157-163.
157. Singh V., Smith W.S., Lawton M.T., et al. Thrombophilic mutation as a new high-risk feature in DAVF patients [abstract]. Ann Neurol 2006, 60:S30.
158. Safavi-Abbasi S., Di Rocco F., Nakaji P., et al. Thrombophilia due to factor V and factor II mutations and formation of a dural arteriovenous fistula: Case report and review of a rare entity. Skull Base 2008, 18(2):135-143.
159. Clatterbuck R.E., Eberhart C.G., Crain B.J., et al. Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J Neurol Neurosurg Psychiatry 2001, 71:188-192.
160. Otten P., Pizzolato G.P., Rilliet B., et al. [131 cases of cavernous angioma (cavernomas) of the CNS, discovered by retrospective analysis of 24,535 autopsies]. Neurochirurgie 1989, 35:82-83. 128-131.
161. Rigamonti D., Hadley M.N., Drayer B.P., et al. Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med 1988, 319:343-347.
162. Labauge P., Laberge S., Brunereau L., et al. Hereditary cerebral cavernous angiomas: Clinical and genetic features in 57 French families. Societe Francaise de Neurochirurgie. Lancet 1998, 352:1892-1897.
163. Labauge P., Brunereau L., Laberge S., et al. Prospective follow-up of 33 asymptomatic patients with familial cerebral cavernous malformations. Neurology 2001, 57:1825-1828.
164. Denier C., Labauge P., Bergametti F., et al. Genotype-phenotype correlations in cerebral cavernous malformations patients. Ann Neurol 2006, 60:550-556.
165. Pozzati E., Acciarri N., Tognetti F., et al. Growth, subsequent bleeding, and de novo appearance of cerebral cavernous angiomas. Neurosurgery 1996, 38:662-669.
166. Maiuri F., Cappabianca P., Gangemi M., et al. Clinical progression and familial occurrence of cerebral cavernous angiomas: The role of angiogenic and growth factors. Neurosurg Focus 2006, 21:e3.
167. Denier C., Labauge P., Brunereau L., et al. Clinical features of cerebral cavernous malformations patients with KRIT1 mutations. Ann Neurol 2004, 55:213-220.
168. Dubovsky J., Zabramski J.M., Kurth J., et al. A gene responsible for cavernous malformations of the brain maps to chromosome 7q. Hum Mol Genet 1995, 4:453-458.
169. Gunel M., Awad I.A., Anson J., et al. Mapping a gene causing cerebral cavernous malformation to 7q11.2-q21. Proc Natl Acad Sci U S A 1995, 92:6620-6624.
170. Marchuk D.A., Gallione C.J., Morrison L.A., et al. A locus for cerebral cavernous malformations maps to chromosome 7q in two families. Genomics 1995, 28:311-314.
171. Johnson E.W., Iyer L.M., Rich S.S., et al. Refined localization of the cerebral cavernous malformation gene (CCM1) to a 4-cM interval of chromosome 7q contained in a well-defined YAC contig. Genome Res 1995, 5:368-380.
172. Gunel M., Awad I.A., Finberg K., et al. A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans. N Engl J Med 1996, 334:946-951.
173. Laberge S., Labauge P., Marechal E., et al. Genetic heterogeneity and absence of founder effect in a series of 36 French cerebral cavernous angiomas families. Eur J Hum Genet 1999, 7:499-504.
174. Craig H.D., Gunel M., Cepeda O., et al. Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. Hum Mol Genet 1998, 7:1851-1858.
175. Liquori C.L., Berg M.J., Siegel A.M., et al. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet 2003, 73:1459-1464.
176. Denier C., Goutagny S., Labauge P., et al. Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet 2004, 74:326-337.
177. Bergametti F., Denier C., Labauge P., et al. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 2005, 76:42-51.
178. Revencu N., Vikkula M. Cerebral cavernous malformation: New molecular and clinical insights. J Med Genet 2006, 43:716-721.
179. Sahoo T., Goenaga-Diaz E., Serebriiskii I.G., et al. Computational and experimental analyses reveal previously undetected coding exons of the KRIT1 (CCM1) gene. Genomics 2001, 71:123-126.
180. Sahoo T., Johnson E.W., Thomas J.W., et al. Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet 1999, 8:2325-2333.
181. Zhang J., Clatterbuck R.E., Rigamonti D., et al. Mutations in KRIT1 in familial cerebral cavernous malformations. Neurosurgery 2000, 46:1272-1277.
182. Eerola I., McIntyre B., Vikkula M. Identification of eight novel 5?-exons in cerebral capillary malformation gene-1 (CCM1) encoding KRIT1. Biochim Biophys Acta 2001, 1517:464-467.
183. Zhang J., Clatterbuck R.E., Rigamonti D., et al. Cloning of the murine Krit1 cDNA reveals novel mammalian 5? coding exons. Genomics 2000, 70:392-395.
184. Serebriiskii I., Estojak J., Sonoda G., et al. Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene 1997, 15:1043-1049.
185. Kitayama H., Sugimoto Y., Matsuzaki T., et al. A ras-related gene with transformation suppressor activity. Cell 1989, 56:77-84.
186. Glading A., Han J., Stockton R.A., et al. KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell cell junctions. J Cell Biol 2007, 179:247-254.
187. Glading A.J., Ginsberg M.H. Rap1 and its effector KRIT1/CCM1 regulate beta-catenin signaling. Dis Model Mech 2010, 3:73-83.
188. Zhang J., Clatterbuck R.E., Rigamonti D., et al. Interaction between krit1 and ICAP1alpha infers perturbation of integrin beta1-mediated angiogenesis in the pathogenesis of cerebral cavernous malformation. Hum Mol Genet 2001, 10:2953-2960.
189. Zawistowski J.S., Serebriiskii I.G., Lee M.F., et al. KRIT1 association with the integrin-binding protein ICAP-1: A new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum Mol Genet 2002, 11:389-396.
190. Denier C., Gasc J.M., Chapon F., et al. Krit1/cerebral cavernous malformation 1 mRNA is preferentially expressed in neurons and epithelial cells in embryo and adult. Mech Dev 2002, 117:363-367.
191. Guzeloglu-Kayisli O., Amankulor N.M., Voorhees J., et al. KRIT1/cerebral cavernous malformation 1 protein localizes to vascular endothelium, astrocytes, and pyramidal cells of the adult human cerebral cortex. Neurosurgery 2004, 54:943-949. discussion 949.
192. Guzeloglu-Kayisli O., Kayisli U.A., Amankulor N.M., et al. Krev1 interaction trapped-1/cerebral cavernous malformation-1 protein expression during early angiogenesis. J Neurosurg 2004, 100:481-487.
193. Whitehead K.J., Plummer N.W., Adams J.A., et al. Ccm1 is required for arterial morphogenesis: Implications for the etiology of human cavernous malformations. Development 2004, 131:1437-1448.
194. Whitehead K.J., Chan A.C., Navankasattusas S., et al. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med 2009, 15:177-184.
195. Boulday G., Blecon A., Petit N., et al. Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: Implications for human cerebral cavernous malformations. Dis Model Mech 2009, 2:168-177.
196. Kleaveland B., Zheng X., Liu J.J., et al. Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway. Nat Med 2009, 15:169-176.
197. Plummer N.W., Squire T.L., Srinivasan S., et al. Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations. Mamm Genome 2006, 17:119-128.
198. Mably J.D., Chuang L.P., Serluca F.C., et al. santa and valentine pattern concentric growth of cardiac myocardium in the zebrafish. Development 2006, 133:3139-3146.
199. Crose L.E., Hilder T.L., Sciaky N., et al. Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells. J Biol Chem 2009, 284:13301-13305.
200. Harel L., Costa B., Tcherpakov M., et al. CCM2 mediates death signaling by the TrkA receptor tyrosine kinase. Neuron 2009, 63:585-591.
201. Zawistowski J.S., Stalheim L., Uhlik M.T., et al. CCM1 and CCM2 protein interactions in cell signaling: Implications for cerebral cavernous malformations pathogenesis. Hum Mol Genet 2005, 14:2521-2531.
202. Adams R.H., Porras A., Alonso G., et al. Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 2000, 6:109-116.
203. Yang J., Boerm M., McCarty M., et al. Mekk3 is essential for early embryonic cardiovascular development. Nat Genet 2000, 24:309-313.
204. Stahl S., Gaetzner S., Voss K., et al. Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: In-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex. Hum Mutat 2008, 29:709-717.
205. Wang H., Chen H., Xia N., et al. cDNA cloning and sequence analysis of hepatitis G virus genome isolated from a Chinese blood donor. Chin Med J (Engl) 1999, 112:747-749.
206. Chen L., Tanriover G., Yano H., et al. Apoptotic functions of PDCD10/CCM3, the gene mutated in cerebral cavernous malformation 3. Stroke 2009, 40:1474-1481.
207. Petit N., Blecon A., Denier C., et al. Patterns of expression of the three cerebral cavernous malformation (CCM) genes during embryonic and postnatal brain development. Gene Expr Patterns 2006, 6:495-503.
208. Tanriover G., Boylan A.J., Diluna M.L., et al. PDCD10, the gene mutated in cerebral cavernous malformation 3, is expressed in the neurovascular unit. Neurosurgery 2008, 62:930-938. discussion 938.
209. Voss K., Stahl S., Schleider E., et al. CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. Neurogenetics 2007, 8:249-256.
210. Gault J., Shenkar R., Recksiek P., et al. Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke 2005, 36:872-874.
211. Kehrer-Sawatzki H., Wilda M., Braun V.M., et al. Mutation and expression analysis of the KRIT1 gene associated with cerebral cavernous malformations (CCM1). Acta Neuropathol 2002, 104:231-240.
212. Lucas M., Costa A.F., Montori M., et al. Germline mutations in the CCM1 gene, encoding Krit1, cause cerebral cavernous malformations. Ann Neurol 2001, 49:529-532.
213. Marini V., Ferrera L., Pigatto F., et al. Search for loss of heterozygosity and mutation analysis of KRIT1 gene in CCM patients. Am J Med Genet A 2004, 130A:98-101.
214. Cave-Riant F., Denier C., Labauge P., et al. Spectrum and expression analysis of KRIT1 mutations in 121 consecutive and unrelated patients with cerebral cavernous malformations. Eur J Hum Genet 2002, 10:733-740.
215. Plummer N.W., Gallione C.J., Srinivasan S., et al. Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. Am J Pathol 2004, 165:1509-1518.
216. Shenkar R., Venkatasubramanian P.N., Wyrwicz A.M., et al. Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models. Neurosurgery 2008, 63:790-797. discussion 797-798.
217. Pagenstecher A., Stahl S., Sure U., et al. A two-hit mechanism causes cerebral cavernous malformations: Complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet 2009, 18:911-918.
218. Detwiler P.W., Porter R.W., Zabramski J.M., et al. Radiation-induced cavernous malformation. J Neurosurg 1998, 89:167-169.
219. Heckl S., AschoffA., Kunze S. Radiation-induced cavernous hemangiomas of the brain: A late effect predominantly in children. Cancer 2002, 94:3285-3291.
220. Larson J.J., Ball W.S., Bove K.E., et al. Formation of intracerebral cavernous malformations after radiation treatment for central nervous system neoplasia in children. J Neurosurg 1998, 88:51-56.
221. Shi C., Shenkar R., Batjer H.H., et al. Oligoclonal immune response in cerebral cavernous malformations. Laboratory investigation. J Neurosurg 2007, 107:1023-1026.
222. Shenkar R., Elliott J.P., Diener K., et al. Differential gene expression in human cerebrovascular malformations. Neurosurgery 2003, 52:465-478.
223. Jung K.H., Chu K., Jeong S.W., et al. Cerebral cavernous malformations with dynamic and progressive course: Correlation study with vascular endothelial growth factor. Arch Neurol 2003, 60:1613-1618.
224. Labauge P., Denier C., Bergametti F., et al. Genetics of cavernous angiomas. Lancet Neurol 2007, 6:237-244.
225. Gault J., Sain S., Hu L.J., et al. Spectrum of genotype and clinical manifestations in cerebral cavernous malformations. Neurosurgery 2006, 59:1278-1284. discussion 1284-1285.
226. Sirvente J., Enjolras O., Wassef M., et al. Frequency and phenotypes of cutaneous vascular malformations in a consecutive series of 417 patients with familial cerebral cavernous malformations. J Eur Acad Dermatol Venereol 2009, 23:1066-1072.
227. Eerola I., Plate K.H., Spiegel R., et al. KRIT1 is mutated in hyperkeratotic cutaneous capillary-venous malformation associated with cerebral capillary malformation. Hum Mol Genet 2000, 9:1351-1355.
228. Labauge P., Krivosic V., Denier C., et al. Frequency of retinal cavernomas in 60 patients with familial cerebral cavernomas: A clinical and genetic study. Arch Ophthalmol 2006, 124:885-886.
229. Eerola I., Boon L.M., Mulliken J.B., et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003, 73:1240-1249.
230. Revencu N., Boon L.M., Mulliken J.B., et al. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum Mutat 2008, 29:959-965.
231. Henkemeyer M., Rossi D.J., Holmyard D.P., et al. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature 1995, 377:695-701.
232. Thiex R., Mulliken J.B., Revencu N., et al. A novel association between RASA1 mutations and spinal arteriovenous anomalies. AJNR Am J Neuroradiol 2010, 31:775-779.
233. Wouters V., Limaye N., Uebelhoer M., et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet 2010, 18:414-420.
234. Singh V., Smith W.S., Lawton M.T., et al. Risk factors for hemorrhagic presentation in patients with dural arteriovenous fistulae. Neurosurgery 2008, 62:628-635. discussion 628-635.
235. Houser O.W., Campbell J.K., Campbell R.J., et al. Arteriovenous malformation affecting the transverse dural venous sinus-an acquired lesion. Mayo Clin Proc 1979, 54:651-661.
236. van Dijk J.M., TerBrugge K.G., Van der Meer F.J., et al. Thrombophilic factors and the formation of dural arteriovenous fistulas. J Neurosurg 2007, 107:56-59.
237. Gerlach R., Yahya H., Rohde S., et al. Increased incidence of thrombophilic abnormalities in patients with cranial dural arteriovenous fistulae. Neurol Res 2003, 25:745-748.
238. Kraus J.A., Stuper B.K., Muller J., et al. Molecular analysis of thrombophilic risk factors in patients with dural arteriovenous fistulas. J Neurol 2002, 249:680-682.
239. Singh V., Meyers P.M., Halbach V.H., et al. Dural arteriovenous fistula associated with prothrombin gene mutation. J Neuroimaging 2001, 11:319-321.
240. Yang G.Y., Xu B., Hashimoto T., et al. Induction of focal angiogenesis through adenoviral vector mediated vascular endothelial cell growth factor gene transfer in the mature mouse brain. Angiogenesis 2003, 6:151-158.